Efficacy and Safety of a New 10% Intravenous Immunoglobulin Product in Patients with Primary Immune Thrombocytopenia (ITP)

BACKGROUND: In the current study, we aimed to investigate the efficacy and safety of intravenous immunoglobulin (IVIg)-SN 10%, a new 10% IVIg formulation, in adult patients with severe primary immune thrombocytopenia (ITP; platelet count < 20 × 10(9)/L). METHODS: Patients diagnosed as primary ITP...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Korean Med Sci
Autors principals: Hong, Junshik, Bang, Soo-Mee, Mun, Yeung-Chul, Yhim, Ho-Young, Lee, Jaehoon, Lim, Hyeong-Seok, Oh, Doyeun
Format: Artigo
Idioma:Inglês
Publicat: The Korean Academy of Medical Sciences 2018
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5934518/
https://ncbi.nlm.nih.gov/pubmed/29736158
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3346/jkms.2018.33.e142
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars